ICANS risk model in CD19 CAR-T therapy: insights from serum and CSF cytokine profiling.

ABSTRACT: Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) is a common and potentially severe complication of CD19 CAR-T therapy. While some clinical risk factors have been described, the contribution of cytokines, particularly in plasma and cerebrospinal fluid (CSF), remains limited. This study aimed to identify predictors and characterize cytokine patterns associated with ICANS to develop a multivariable risk model. We retrospectively analyzed 101 adult patients treated with axicabtagene ciloleucel (axi-cel) or tisagenlecleucel (tisa-cel) between 2019 and 2023. Cytokines (interleukin (IL)-1β, IL-6, IL-15, GM-CSF) were measured in plasma pre- and post-infusion, and in CSF during neurotoxicity. ICANS occurred in 36% of patients, more frequently with axi-cel (46% vs. 21%, p < 0.05). Aut

SUBMITTER: Gomez-Llobell M 

PROVIDER: S-EPMC12568627 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature